Turning point therapeutics, inc. (TPTX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Operating activities
Net loss

-60,718

-20,959

-20,483

-17,142

-13,547

-9,018

-5,997

-5,037

-4,733

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

38,365

4,228

3,493

3,059

1,926

746

179

137

85

Depreciation

208

170

89

158

75

74

25

21

18

Accretion of discount on marketable securities

242

-

-

-

-

-

-

-

-

Amortization of right-of-use operating lease asset

380

-

-

-

164

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

2,819

684

797

2,965

856

-137

-405

199

255

Accounts payable

-28

-293

-1,399

1,000

1,595

-625

240

-458

724

Accrued expenses and other current liabilities

946

644

124

-1,300

1,054

312

-345

16

-928

Accrued compensation

-3,958

2,953

2,112

857

-599

551

364

362

-299

Operating lease right-of-use assets and liabilities, net

-

-

-

-

-

-

-

3

4

Net cash used in operating activities

-27,866

-14,072

-16,546

-16,951

-10,188

-7,858

-5,122

-5,161

-5,392

Investing activities
Purchases of marketable securities

63,675

-

-

-

-

-

-

-

-

Sales and maturities of marketable securities

73,620

-

-

-

-

-

-

-

-

Purchases of property and equipment

454

761

795

155

33

81

83

27

111

Net cash provided by (used in) investing activities

9,491

-110,110

-80,096

-170,840

-33

-81

-83

-27

-111

Financing activities
Costs paid in connection with initial public offering

-

-

-

-

819

-

-

-

-

Proceeds from issuance of common stock

25

-

-

-

22

-

-

-

-

Proceeds from issuance of common stock from stock option exercises

-

-

-

-

-

-

26

39

6

Net cash provided by (used in) financing activities

25

-51

190,282

176,561

-797

79,760

26

39

6

Net decrease in cash and cash equivalents

-18,350

-124,233

93,640

-11,230

-11,018

71,821

-5,179

-5,149

-5,497

Supplemental disclosure of cash flow information:
Cash paid for income taxes

1

0

0

0

1

0

0

0

1

Supplemental disclosure of non-cash investing and financing information:
Costs incurred in connection with the initial public offering included in accounts payable and accrued expenses

-

-

-

-

760

-

-

-

-

Operating lease liabilities arising from obtaining right-of-use assets

-

0

4,034

-753

2,273

-

-

-

-